全球蛋白質變性療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球蛋白質變性療法市場預計將從2025年的17.5億美元成長至2034年的37億美元，2026年至2034年的複合年成長率（CAGR）為8.67%。隨著醫療專業人員和研究人員致力於治療與蛋白質異常累積和變性相關的疾病，該市場正蓬勃發展。生物技術和分子醫學的進步加深了我們對蛋白質相關疾病的理解，並為創新療法創造了機會。神經退化性疾病退化性疾病和罕見疾病的日益普遍進一步推動了對標靶治療方案的需求。

推動這一市場發展的因素包括生物醫學研究投入的增加、臨床開發項目的擴展以及人們對蛋白質相關疾病認知的提高。製藥公司正在尋求能夠解決疾病根本機制的先進治療方法，而不僅僅是控制症狀。此外，監管政策的支持和對罕見疾病研究投入的增加也促進了市場成長。

前景十分光明，基因療法、精準醫療和生物製藥領域的突破性進展不斷拓展治療選擇。正在進行的臨床試驗和技術創新有望提高治療效果和患者預後。隨著我們對蛋白質退化性疾病的科學認知不斷加深，該市場預計將迎來顯著的長期成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：本節詳細評估影響市場成長的主要促進因素、阻礙因素、機會和挑戰。內容涵蓋技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球蛋白質變性療法市場：按類型分類

• 市場分析、洞察與預測
• 巴夫德加胺（ARV-110）
• 貝普德格斯特蘭（ARV-471）
• 其他類型

第5章 全球蛋白質變性治療市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 神經退化性疾病
• 感染疾病
• 其他用途

第6章 全球蛋白質變性治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 製藥公司
• 生技公司
• 學術研究機構

第7章 全球蛋白質變性療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Relay Therapeutics Inc
  • Kymera Therapeutics Inc
  • Nurix Therapeutics Inc
  • Vividion Therapeutics Inc
  • Mission Therapeutics Ltd
  • C4 Therapeutics Inc
  • Frontier Medicines Inc
  • Foghorn Therapeutics Inc
  • Aileron Therapeutics Inc
  • Ribometrix Inc
  • Nimbus Therapeutics Inc
  • Jnana Therapeutics Inc
  • KSQ Therapeutics Inc
  • Stoke Therapeutics Inc

The global protein degeneration therapy market size is expected to reach USD 3.70 Billion in 2034 from USD 1.75 Billion in 2025, growing at a CAGR of 8.67 during 2026-2034.This market has gained momentum as healthcare providers and researchers focus on treating diseases associated with abnormal protein accumulation and degeneration. Advances in biotechnology and molecular medicine have improved understanding of protein-related disorders, creating opportunities for innovative therapeutic approaches. Growing prevalence of neurodegenerative and rare diseases has further increased demand for targeted treatment solutions.

The market is driven by rising investments in biomedical research, expanding clinical development programs, and growing awareness of protein-related disorders. Pharmaceutical companies are exploring advanced therapies designed to address underlying disease mechanisms rather than merely managing symptoms. Supportive regulatory initiatives and increased funding for rare disease research are also contributing to market growth.

Future prospects are highly promising as breakthroughs in gene therapy, precision medicine, and biologics continue advancing treatment possibilities. Ongoing clinical trials and technological innovations are expected to improve therapeutic effectiveness and patient outcomes. As scientific understanding of protein degeneration disorders expands, the market is likely to witness significant long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Bavdegalutamide (ARV-110)
• Vepdegestrant (ARV-471)
• Other Types

By Application

• Oncology
• Neurodegenerative Diseases
• Infectious Diseases
• Other Applications

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes

COMPANIES PROFILED

• Arvinas Holding Company LLC, Relay Therapeutics Inc., Kymera Therapeutics Inc., Nurix Therapeutics Inc., Vividion Therapeutics Inc., Mission Therapeutics Ltd., C4 Therapeutics Inc., Frontier Medicines Inc., Foghorn Therapeutics Inc., Aileron Therapeutics Inc., Ribometrix Inc., Nimbus Therapeutics Inc., Jnana Therapeutics Inc., KSQ Therapeutics Inc., Stoke Therapeutics Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Bavdegalutamide (ARV-110) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vepdegestrant (ARV-471) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTEIN DEGENERATION THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROTEIN DEGENERATION THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Relay Therapeutics Inc
  • 9.2.2 Kymera Therapeutics Inc
  • 9.2.3 Nurix Therapeutics Inc
  • 9.2.4 Vividion Therapeutics Inc
  • 9.2.5 Mission Therapeutics Ltd
  • 9.2.6 C4 Therapeutics Inc
  • 9.2.7 Frontier Medicines Inc
  • 9.2.8 Foghorn Therapeutics Inc
  • 9.2.9 Aileron Therapeutics Inc
  • 9.2.10 Ribometrix Inc
  • 9.2.11 Nimbus Therapeutics Inc
  • 9.2.12 Jnana Therapeutics Inc
  • 9.2.13 KSQ Therapeutics Inc
  • 9.2.14 Stoke Therapeutics Inc